Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

Patients who switched from weekly to monthly maintenance dosing of an experimental Pfizer obesity drug achieved an average placebo-adjusted weight loss of up to 12.3% in a mid-stage study, results ...

The MarketWatch News Department was not involved in the creation of this content. -- VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher ...

Pfizer (PFE) stock hold rating: 2026 patent cliff, falling Covid sales, GLP-1 obesity timeline, and M&A integration risks—read the outlook now.

Pfizer Inc. delivered a 17% total return since early November, but fundamentals lag and valuation isn’t compelling. Read more ...

The anti-obesity drug market could be worth a staggering $100 billion, according to some analysts. That's a huge growth opportunity, and it's a reason why many top drugmakers in the world are spending ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

It might be a good idea for short-term investors to avoid this Zacks Rank #5 (Strong Sell) stock for now. However, long-term ...

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if ...